Navigation Links
Mindray Announces First Quarter 2011 Financial Results
Date:5/9/2011

SHENZHEN, China, May 9, 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the first quarter ended March 31, 2011.

Highlights for First Quarter 2011

  • Net revenues were $180.9 million, an increase of 24.0% over the first quarter of 2010.
  • Robust international sales of $108.5 million, a year-over-year increase of 29.6%. Emerging markets and developed markets both achieved significant growth this quarter.
  • Total China sales achieved 16.6% year-over-year growth, with solid non-tender sales increase of 23.1% year-over-year.
  • GAAP net income was $37.7 million, a 4.2% year-over-year increase. Excluding the tax benefit of $7.6 million and $8.6 million recognized in the first quarter of 2011 and 2010 respectively, non-GAAP net income increased 9.9% over the first quarter of 2010(Note).
  • EBITDA in the first quarter of 2011 was $40.8 million, a year-over-year increase of 5.2%.
  • Net operating cash generated during the quarter was $32.3 million.
  • Mindray introduced three new products during the quarter, including the A5 anesthesia machine, the BeneHeart D3 defibrillator and the DP-50 black and white ultrasound system.

  • "We had a good start to the year and are happy to report a 24.0% year-over-year increase in revenues, driven primarily by this quarter's robust international sales growth of nearly 30%," commented Xu Hang, Mindray's chairman and co-chief executive officer. "We are pleased with the strong sales growth and momentum in both emerging and developed markets. Latin America, Asia Pacific and Western Europe all achieved more than 40% year over year growth, while North America grew over 20% during the period. In China, non-tender sales maintained its recovery trend from last quarter, growing 23.1% year-over-year. We expect international sales to remain our key driver this year. We are also optimistic about our initiatives in the China market and expect continued, gradual improvement in our China business."

    SUMMARY –First quarter2011(in $ millions, except per-share data)

    Three Months EndedMarch 312011

    2010

    % chgNet Revenues

    180.9

    145.8

    24.0%Revenues generated outside China

    108.5

    83.7

    29.6%Revenues generated in China

    72.5

    62.2

    16.6%Gross Profit

    99.7

    82.3

    21.2%Non-GAAP Gross Profit

    101.0

    83.9

    20.5%Operating Income

    33.0

    31.9

    3.5%Non-GAAP Operating Income

    37.6

    35.9

    4.5%EBITDA

    40.8

    38.8

    5.2%Net Income

    37.7

    36.2

    4.2%Non-GAAP Net Income

    42.2

    40.1

    5.2%Non-GAAP Net Income (ex tax benefit -Note)

    34.6

    31.5

    9.9%Diluted EPS

    0.32

    0.31

    2.2%Non-GAAP Diluted EPS

    0.36

    0.35

    3.1%Note: The amount excludes the tax benefits of $7.6 million and $8.6 million for the three months ended March 31, 2011 and 2010 respectively. The tax benefits are related to the nationwide key software enterprise status for the calendar year 2010 and 2009, awarded to our Shenzhen subsidiary in February 2011 and January 2010 respectively.

    RevenuesMindray reported net revenues of $180.9 million for the first quarter of 2011, a 24.0% increase from $145.8 million in the first quarter of 2010. Net revenues generated in international markets in the first quarter of 2011 increased 29.6% to $108.5 million from $83.7 million in the first quarter of 2010, while net revenues generated in China in the first quarter of 2011 increased 16.6% to $72.5 million from $62.2 million in the first quarter of 2010.

    Performance by SegmentPatient Monitoring & Life Support Products: Patient monitoring & life support products segment revenues increased 26.6% to $78.1 million from $61.7 million in the first quarter of 2010. The patient monitoring & life support products segment contributed 43.2% to total net revenues in the first quarter of 2011.

    In-Vitro Diagnostic Products: In-vitro diagnostic products segment revenues increased 22.0% to $46.3 million from $37.9 million in the first quarter of 2010. The in-vitro diagnostic products segment contributed 25.6% to total net revenues in the first quarter of 2011.

    Medical Imaging Systems: Medical imaging systems segment revenues increased 28.1% to $47.6 million from $37.1 million in the first quarter of 2010. The medical imaging systems segment contributed 26.3% to total net revenues in the first quarter of 2011.

    Others: Other revenues, which are primarily comprised of service fees charged for post warranty period repair services, decreased 1.9% to $8.9 million from $9.1 million in the first quarter of 2010. Other revenues contributed 4.9% to total net revenues in the first quarter of 2011.

    Gross MarginsFirst quarter 2011 gross profit was $99.7 million, a 21.2% increase from $82.3 million in the first quarter of 2010. First quarter 2011 non-GAAP gross profit was $101.0 million, a 20.5% increase from $83.9 million in the first quarter of 2010. First quarter 2011 gross margin was 55.1% compared to 56.4% in the first quarter of 2010 and 54.7% in the fourth quarter of 2010. Non-GAAP gross margin was 55.9% in the first quarter of 2011 compared to 57.5% in the first quarter of 2010 and 55.2% in the fourth quarter of 2010.

    Operating ExpensesSelling expenses for the first quarter of 2011 were $33.7 million, or 18.6% of total net revenues, compared to 16.2% in the first quarter of 2010 and 19.9% in the fourth quarter of 2010. Non-GAAP selling expenses for the first quarter of 2011 were $32.0 million, or 17.7% of total net revenues, compared to 15.3% in the first quarter of 2010 and 19.2% in the fourth quarter of 2010.

    General and administrative expenses for the first quarter of 2011 were $14.4 million, or 8.0% of total net revenues, compared to 8.4% in the first quarter of 2010 and 8.7% in the fourth quarter of 2010. Non-GAAP general and administrative expenses for the first quarter of 2011 were $13.9 million, or 7.7% of the total net revenues, compared to 8.1% in the first quarter of 2010 and 8.5% in the fourth quarter of 2010.

    Research and development expenses for the first quarter of 2011 were $18.6 million, or 10.3% of total net revenues, compared to 9.9% in the first quarter of 2010 and 7.9% in the fourth quarter of 2010. Non-GAAP research and development expenses for the first quarter of 2011 were $17.6 million, or 9.7% of total net revenues, compared to 9.4% in the first quarter of 2010 and 7.7% in the fourth quarter of 2010.

    Total share-based compensation expenses, which were allocated to cost of revenues and related operating expenses, were $2.8 million in the first quarter of 2011 compared to $1.7 million in the fourth quarter of 2010 and $1.9 million in the first quarter of 2010.

    Operating income was $33.0 million in the first quarter of 2011, a 3.5% increase from $31.9 million in the first quarter of 2010. Non-GAAP operating income in the first quarter of 2011 was $37.6 million, a 4.5% increase from $35.9 million in the first quarter of 2010. Operating margin was 18.3% in the first quarter of 2011 compared to 21.9% in the first quarter of 2010 and 17.7% in the fourth quarter of 2010. Non-GAAP operating margin was 20.8% in the first quarter of 2011 compared to 24.6% in the first quarter of 2010 and 19.8% in the fourth quarter of 2010.

    Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA")First quarter 2011 EBITDA increased 5.2% year-over-year to $40.8 million from $38.8 million in the first quarter of 2010 and decreased 23.4% from $53.3 million in the fourth quarter of 2010.

    Net IncomeNet income increased 4.2% year-over-year to $37.7 million from $36.2 million in the first quarter of 2010. Non-GAAP net income increased 5.2% year-over-year to $42.2 million from $40.1 million in the first quarter of 2010. Net margin was 20.8% in the first quarter of 2011 compared to 24.8% in the first quarter of 2010 and 19.5% in the fourth quarter of 2010. Non-GAAP net margin was 23.3% in the first quarter of 2011 compared to 27.5% in the first quarter of 2010 and 21.5% in the fourth quarter of 2010. First quarter 2011 income tax benefits in the first quarter were $1.0 million, resulting from the recognition of $7.6 million corporate income tax reduction in the first quarter of 2011 which relates to the nationwide key software enterprise status for the calendar year 2010, awarded to our Shenzhen subsidiary in February 2011.

    First quarter 2011 basic and diluted earnings per share were $0.33 and $0.32, respectively, compared to $0.33 and $0.31 in the first quarter of 2010. Basic and diluted non-GAAP earnings per share were $0.37 and $0.36, respectively, compared to $0.36 and $0.35 in the first quarter of 2010. Shares used in the computation of diluted earnings per share for the first quarter 2011 were 118.0 million.

    Other Select DataAverage accounts receivable days outstanding were 72 days in the first quarter of 2011 compared to 59 days in the fourth quarter of 2010. Average inventory days were 94 days in the first quarter of 2011 compared to 82 days in the fourth quarter of 2010. Average accounts payable days outstanding were 58 days in the first quarter of 2011 compared to 45 days in the fourth quarter of 2010. Mindray calculates the above working capital days using the average of beginning and ending balances of the quarter.

    As of March 31, 2011, the company had $442.6 million in cash and cash equivalents, and short-term investments as compared to $433.5 million as of December 31, 2010. Net cash generated from operating activities and net cash outflow for capital expenditures during the quarter were $32.3 million and $27.3 million respectively.

    As of March 31, 2011, the company had 6,587 employees.

    Business Outlook for Full Year 2011The company maintains its full year guidance and expects its full year 2011 net revenues to be more than 16% higher than its full year 2010 net revenues.

    The company continues to expect its full year 2011 non-GAAP net income to grow more than 10% over its non-GAAP net income for full year 2010. This guidance excludes the tax benefits related to the key software enterprise status ($8.6 million recognized in the first quarter of 2010 and $7.6 million recorded in the first quarter of 2011) and assumes a corporate income tax rate of 15% applicable to the Shenzhen subsidiary.

    The company expects its capital expenditure for 2011 to remain in the range of $70 million to $80 million.

    The company's practice is to provide guidance on a full year basis only. This forecast reflects Mindray's current and preliminary views, which are subject to change.

    "We are maintaining our guidance at this time. In the first quarter, we were pleased with our performance in the international markets, as well as the sales improvement resulting from our strategic initiatives in China," commented Li Xiting, Mindray's president and co-chief executive officer. "The overall growth prospects of our key international markets continue to be positive, although we are closely monitoring the political situations in the Middle East and Africa. We also firmly believe that China's healthcare sector investment environment remains favorable, which bodes well for leading companies like Mindray. Based on our commitment to invest in international markets, the implementation of our initiatives in China, coupled with the Chinese government's renewed focus on county level hospitals, as well as our dedicated R&D effort, we are confident that Mindray is well-positioned for future growth and expansion."

    Conference Call InformationMindray's management will hold an earnings conference call at 8:00 AM on May 10, 2011 U.S. Eastern Time (8:00 PM on May 10, 2011 Beijing/Hong Kong Time).

    Dial-in details for the earnings conference call are as follows:

    U.S. Toll Free:

    +1-866-804-6923International:

    +1-857-350-1669Hong Kong:

    +852-3002-1672Pass code for all regions: Mindray

    A replay of the conference call may be accessed by phone at the following numbers until May 23, 2011.

    U.S. Toll Free:

    +1-888-286-8010International:

    +1-617-801-6888Passcode:

    9389-5400Additionally, a live and archived webcast of this conference call will be available on the Investor Relations section of Mindray's website at http://ir.mindray.com.

    Use of Non-GAAP Financial Measures Mindray provides gross profit, selling expenses, general and administrative expenses, R&D expenses, operating income, net income and earnings per share on a non-GAAP basis that excludes share-based compensation expense and acquired intangible assets amortization expense, all net of related tax impact, as well as EBITDA to enable investors to better assess the company's operating performance. The non-GAAP measures described by the company are reconciled to the corresponding GAAP measure in the exhibit below titled "Reconciliations of non-GAAP results of operations measures to the nearest comparable GAAP measures".

    The company has reported for the first quarter of 2011 and provided guidance for full year 2011 earnings on a non-GAAP basis. Each of the terms as used by the company is defined as follows:

  • Non-GAAP gross profit represents gross profit reported in accordance with GAAP, adjusted for the effects of share-based compensation and amortization of acquired intangible assets.
  • Non-GAAP operating income represents operating income reported in accordance with GAAP, adjusted for the effects of share-based compensation, and amortization of acquired intangible assets.
  • Non-GAAP selling expenses represent selling expenses reported in accordance with GAAP, adjusted for the effects of share-based compensation, and amortization of acquired intangible assets.
  • Non-GAAP general and administrative expenses represent general and administrative expenses reported in accordance with GAAP, adjusted for the effects of share-based compensation.
  • Non-GAAP research and development expenses represent research and development expenses reported in accordance with GAAP, adjusted for the effects of share-based compensation.
  • Non-GAAP net income represents net income reported in accordance with GAAP, adjusted for the effects of share-based compensation and amortization of acquired intangible assets, all net of related tax impact.
  • Non-GAAP earnings per share represents non-GAAP net income divided by the number of shares used in computing basic and diluted earnings per share in accordance with GAAP, and excludes the impact of the declared dividends for the basic calculation.
  • EBITDA represents net income reported in accordance with GAAP, adjusted for the effect of interest income and expenses, provision of income taxes, depreciation and amortization.

  • The company computes its non-GAAP financial measures using the same consistent method from quarter to quarter. The company notes that these measures may not be calculated on the same basis of similar measures used by other companies. Readers are cautioned not to view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies, and should refer to the reconciliation of GAAP results with non-GAAP results for the three months ended March 31, 2010 and 2011, respectively, in the attached financial information.

    Cautionary Note Regarding Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about Mindray's anticipated net revenues, non-GAAP net income and capital expenditure for 2011, our ability to restore growth in non-tender sales, projected growth of our market share in 2011, projected growth of net revenues in 2011, our ability to grow profits and market share, new market penetration, expansion of our presence in emerging markets, improving our developed market sales capabilities and improving the effectiveness of our working capital utilization are forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors. The financial information contained in this release should be read in conjunction with the consolidated financial statements and notes thereto included in our public filings with the Securities and Exchange Commission. For a discussion of other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 7 of our annual report on Form 20-F. Our results of operations for the first quarter of 2011 are not necessarily indicative of our operating results for any future periods. Any projections in this release are based on limited information currently available to us, which is subject to change. Although such projections and the factors influencing them will likely change, we will not necessarily update the information. Such information speaks only as of the date of this release.

    About MindrayWe are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain global headquarters in Shenzhen, China, U.S. headquarters in Mahwah, New Jersey and multiple sales offices in major international markets. From our main manufacturing and engineering base in China and through our worldwide distribution network, we are able to supply internationally a broad range of products across three primary business segments, comprised of patient monitoring and life support products, in-vitro diagnostic products and medical imaging systems. For more information, please visit http://ir.mindray.com.

    For investor and media inquiries please contact:

    In the U.S:Hoki LukWestern Bridge, LLCTel:   +1-646-808-9150Email: hoki.luk@westernbridgegroup.comIn China: Cathy GaoMindray Medical International LimitedTel: +86-755-8188-8023Email: cathy.gao@mindray.comExhibit 1MINDRAY MEDICAL INTERNATIONAL LIMITEDCONDENSED CONSOLIDATED BALANCE SHEETS(Dollars in thousands)As of December 31, 2010 As of March 31, 2011 US$ US$ (Note 1) (unaudited) ASSETSCurrent assets:Cash and cash equivalents137,502118,746Short-term investments 296,003323,836Accounts receivable, net143,318144,354Inventories79,18588,625Value added tax receivables18,56220,470Other receivables9,95311,400Prepayments and deposits7,5968,590Deferred tax assets 2,4812,797Total current assets694,600718,818Other assets4,5525,306Advances for purchase of plant and equipment15,77511,232Property, plant and equipment, net207,636212,665Land use rights, net 46,07946,125Intangible assets, net66,24767,795Goodwill115,672115,791Total assets1,150,5611,177,732LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilities:Notes payable5,7735,632Accounts payable44,32248,441Advances from customers13,20913,918Salaries payables26,77017,596Other payables66,61587,872Income taxes payable13,58211,866Other taxes payable4,2863,646Total current liabilities174,557188,971Other long-term payables1,1331,518Deferred tax liabilities, net8,2688,8249,40110,342Shareholders' equity:Ordinary shares1515Additional paid-in capital466,613470,627Retained earnings434,143437,171Accumulated other comprehensive income65,83070,604Total shareholders' equity966,601978,417Non-controlling interest22Total equity966,603978,419Total liabilities and shareholders' equity1,150,5611,177,732(1) Financial information is extracted from the audited financial statements included in the Company's fiscal 2010 Form 20F.Exhibit 2MINDRAY MEDICAL INTERNATIONAL LIMITEDCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Dollars in thousands, except for share and per share data)   Three months ended March 31, 2010 2011 US$ US$ (unaudited) (unaudited) Net revenues- International

    83,691108,451-PRC

    62,15472,453Net revenues

    145,845180,904Cost of revenues

    (63,595)(81,185)Gross profit

    82,25099,719Selling expenses

    (23,664)(33,672)General and administrative expenses

    (12,246)(14,427)Research and development expenses

    (14,435)(18,588)Operating income

    31,90533,032Other income, net

    117426Interest income

    2,1343,509Interest expense

    (1,406)(220)Income before income taxes and non-controlling interests

    32,75036,747Income tax benefits

    3,447963Net income

    36,19737,710Less: Net income attributable to non-controlling interests

    --Net income attributable to the Company

    36,19737,710Basic earnings per share

    0.330.33Diluted earnings per share

    0.310.32Shares used in the computation of:Basic earnings per share

    111,242,484114,847,103Diluted earnings per share

    115,743,576118,015,520Exhibit 3MINDRAY MEDICAL INTERNATIONAL LIMITEDCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Dollars in thousands)Three months ended March 31, 2010 2011 US$ US$ (unaudited) (unaudited) Cash flow from operating activities:  Net income

    36,19737,710  Adjustments to reconcile net income to net cash from operating activities

    8,16512,314  Changes in current assets and liabilities

    (11,566)(17,726)Net cash generated from operating activities32,79632,298Cash flow from investing activities:   Capital expenditure

    (15,431)(27,316)   Decrease in restricted cash

    22,623-   Proceeds from sale of restricted/short term investments

    91,91685,692   Increase in short term investments and changes in other investing activities

    (121,911)(111,349)Net cash used in investing activities(22,803)(52,973)Cash flow from financing activities:   Repayment of bank loans

    (115,000)-   Proceeds from exercise of options

    6,1481,235   Net proceeds from secondary public offering

    149,661-Net cash generated from financing activities40,8091,235Net increase/(decrease) in cash and cash equivalents50,802(19,440)Cash and cash equivalents at beginning of period

    204,228137,502Effect of exchange rate changes on cash

    54684Cash and cash equivalents at end of period255,084118,746Exhibit 4MINDRAY MEDICAL INTERNATIONAL LIMITEDRECONCILIATIONS OF NON-GAAP RESULTS OF OPERATIONS MEASURES TO THE NEAREST COMPARABLE GAAP MEASURES(Dollars in thousands, except for share and per share data)Three months ended March 31, 2010 2011 (unaudited)(unaudited) US$ US$ Non-GAAP net income40,14542,222Non-GAAP net margin

    27.5%23.3%Amortization of acquired intangible assets

    (2,132)(1,767)Deferred tax impact related to acquired intangible assets

    9034Share-based compensation

    (1,906)(2,779)GAAP net income

    36,19737,710GAAP net margin

    24.8%20.8%Non-GAAP basic earnings per share

    0.360.37Non-GAAP diluted earnings per share

    0.350.36GAAP basic earnings per share

    0.330.33GAAP diluted earnings per share

    0.310.32 Shares used in computation of: Basic earnings per share

    111,242,484114,847,103 Diluted earnings per share

    115,743,576118,015,520Non-GAAP operating income35,94337,578Non-GAAP operating margin

    24.6%20.8%Amortization of acquired intangible assets

    (2,132)(1,767)Share-based compensation

    (1,906)(2,779)GAAP operating income

    31,90533,032GAAP operating margin

    21.9%18.3%Non-GAAP gross profit83,859101,041Non-GAAP gross margin

    57.5%55.9%Amortization of acquired intangible assets

    (1,510)(1,144)Share-based compensation

    (99)(178)GAAP gross profit

    82,25099,719GAAP gross margin

    56.4%55.1%Non-GAAP selling expenses(22,377)(31,966)Non-GAAP as % of total revenues

    15.3%17.7%Amortization of acquired intangible assets

    (622)(623)Share-based compensation

    (665)(1,083)GAAP selling expenses

    (23,664)(33,672)GAAP as % of total revenues

    16.2%18.6%Non-GAAP general and administrative expenses(11,768)(13,928)Non-GAAP as % of total revenues

    8.1%7.7%Share-based compensation

    (478)(499)GAAP general and administrative expenses

    (12,246)(14,427)GAAP as % of total revenues

    8.4%8.0%Non-GAAP research and development expenses(13,771)(17,569)Non-GAAP as % of total revenues

    9.4%9.7%Share-based compensation

    (664)(1,019)GAAP research and development expenses

    (14,435)(18,588)GAAP as % of total revenues

    9.9%10.3%Exhibit 5MINDRAY MEDICAL INTERNATIONAL LIMITEDRECONCILIATION OF GAAP NET INCOME TO EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION AND AMORTIZATION(Dollars in thousands)Three months ended March 31, 2010 2011 US$US$(unaudited)(unaudited)GAAP net income

    36,19737,710Interest income

    (2,134)(3,509)Interest expense

    1,406220Income tax benefits

    (3,447)(963)Earnings before interest and taxes ("EBIT")

    32,02233,458Depreciation

    4,5335,048Amortization

    2,2502,323Earnings before interest, taxes, depreciation, and amortization ("EBITDA")

    38,80540,829
    '/>"/>

    SOURCE Mindray Medical International Limited
    Copyright©2010 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Mindray Files Annual Report on Form 20-F with U.S. Securities and Exchange Commission
    2. Mindray to Report First Quarter 2011 Financial Results on May 9, 2011
    3. Mindray Medical to Exhibit New Products at 65th China International Medical Equipment Fair
    4. Mindray Appoints Mr. Jie Liu as Chief Financial Officer
    5. Mindray Medical to Present at the 14th Annual Credit Suisse Asian Investment Conference on March 21-25
    6. Mindray Medical to Acquire a Controlling Stake in Shenke Medical
    7. Mindray Announces 2010 Fourth Quarter and Full Year Results
    8. Mindray Announces FDA 510(k) Clearance of Its A5 Anesthesia System
    9. Mindray to Report Fourth Quarter and Full Year 2010 Financial Results on February 28, 2011
    10. Mindray Receives its Largest Order of Patients Monitors in Canada
    11. Mindray Medical to Exhibit at Arab Health 2011 in Dubai from January 24-27
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/4/2016)... , Feb. 4, 2016 For hospitals ... or those already participating in the program, the Health ... referred to as the , Mega-Guidance , could have ... guidance is published in September 2016. Essential ... and Service Marketing , summarizes the Mega-Guidance,s key proposed ...
    (Date:2/4/2016)... -- Worldwide Radiology Oncology surgical robot markets are ... systems provide a way to improve traditional open ... systems pinpoint the delivery of radiation precisely, eliminating ... problem previously, limiting the quantity of radiation that ... far beyond what has been available, promising a ...
    (Date:2/4/2016)... , Feb. 4, 2016 Wegener ... Global Markets Direct,s, ,Wegener Polyangiitis - Pipeline ... Wegener Polyangiitis,s therapeutic pipeline. This report provides ... Polyangiitis, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ...
    Breaking Medicine Technology:
    (Date:2/5/2016)... ... 05, 2016 , ... In the fourth quarter of 2015, ... the La Valencia Hotel in San Diego, California to discuss changes in the ... most outstanding franchise, walking away with the coveted David Wright Award of Excellence. ...
    (Date:2/5/2016)... ... 05, 2016 , ... Pivot Point Consulting, a leading national ... & Services for HIT Implementation Support & Staffing report with an outstanding score ... by healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 clinics. ...
    (Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Colorize ... from on one drop zone to the next using Colorize's dynamic moving camera. Colorize ... project. This package includes a 3D slideshow environment with 1 to 5 focus points ...
    (Date:2/5/2016)... , ... February 05, 2016 , ... Calls Blacklist has ... completely new user interface design and the developer has fixed known bugs within the ... want to on their phone while not consuming any of their device’s battery power ...
    (Date:2/4/2016)... (PRWEB) , ... February 04, 2016 , ... ... "It's All About YOU Re-Treat" on February 19-21, 2016, in Southern California ... at Rancho Palos Verdes, California. These 30 professional speakers, including Clinical Psychologist and ...
    Breaking Medicine News(10 mins):